“…Several studies conducted in patients with gynaecologic cancers have identified dAEs as one of the most significant toxicities limiting quality of life (QoL) and as leading factors impairing functional, emotional, physical and social well-being in cancer patients (Gandhi, Oishi, Zubal, & Lacouture, 2010;Hackbarth, Haas, Fotopoulou, Lichtenegger, & Sehouli, 2008; Ra et al, 2013;Sibaud et al, 2016), especially because they often persist long after completion of chemotherapy (Gandhi et al, 2010).…”